Edition:
Deutschland

Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

83.32EUR
20 Sep 2019
Change (% chg)

€1.90 (+2.33%)
Prev Close
€81.42
Open
€81.50
Day's High
€83.32
Day's Low
€81.17
Volume
8,017,591
Avg. Vol
2,374,199
52-wk High
€83.32
52-wk Low
€71.74

About

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality... (more)

Buy/Sell

Sell Hold Buy
2.00 Mean rating from 26 analysts

Overall

Beta: 0.93
Market Cap(Mil.): €108,903.00
Shares Outstanding(Mil.): 1,262.50
Dividend: 2.96
Yield (%): 3.43
Photo

Novartis halts distribution of its Zantac versions amid probe into impurities

Novartis AG's Sandoz unit said on Wednesday it was halting distribution of its versions of the drug commonly known as Zantac in all its markets, including the United States and Canada, after contaminants were found in the heartburn drug.

Novartis halts distribution of its Zantac versions amid probe into impurities

Sept 18 Novartis AG's Sandoz unit said on Wednesday it was halting distribution of its versions of the drug commonly known as Zantac in all its markets, including the United States and Canada, after contaminants were found in the heartburn drug.

Photo

With a backup to the backup, insulin makers say they're primed for Brexit

LONDON For two men trained as scientists, the bosses of Britain's major insulin providers have had to become experts in ferry schedules, trucking laws and warehouse capacity as they seek to guarantee the supply of life-saving drugs through a chaotic Brexit. | Video

Photo

Factbox: Britain's insulin providers prepare for Brexit fallout

LONDON With Britain sourcing the vast majority of the insulin needed by its 1 million diabetics from overseas, its biggest providers have had to restructure their supply chains in case a chaotic Brexit disrupts the normal arteries of trade.

FACTBOX-Britain's insulin providers prepare for Brexit fallout

LONDON, Sept 17 With Britain sourcing the vast majority of the insulin needed by its 1 million diabetics from overseas, its biggest providers have had to restructure their supply chains in case a chaotic Brexit disrupts the normal arteries of trade.

Happify Health and Sanofi team up on multiple sclerosis treatments

* Happify Health, a global leader in mental health technology, today announced it signed an agreement with global biopharmaceutical company Sanofi to advance the application of digital therapeutics to address key co-morbidities for individuals living with multiple sclerosis (MS), including depression and anxiety.

French and Benelux stocks-Factors to watch on

Sept 16 Below are company-related news and stories from French and Benelux media which could have an impact on the region's markets or individual stocks.

Photo

U.S and European regulators reviewing safety of heartburn drugs like Zantac

U.S. and European drug regulators said on Friday they are reviewing the safety of the widely taken heartburn drug ranitidine, commonly known by the brand name Zantac, after they found traces of a probable cancer-causing impurity in some versions of the medicine.

UPDATE 3-U.S and European regulators reviewing safety of heartburn drugs like Zantac

Sept 13 U.S. and European drug regulators said on Friday they are reviewing the safety of the widely taken heartburn drug ranitidine, commonly known by the brand name Zantac, after they found traces of a probable cancer-causing impurity in some versions of the medicine.

Märkte

  • U.S.
  • Europa
  • Asien
  • Branchen

Branchenüberblick

Energie -0.08%
Rohstoffe -0.55%
Industrie -0.61%
Konjunktur abhängige Waren & Dienstleistungen -0.28%
Konjunktur unabhängige Waren & Dienstleistungen -0.19%
Finanzindustrie +0.60%
Pharma -0.87%
Technologie +0.65%
Telekommunikation +0.19%